UFP Technologies Inc. Common Stock (UFPT)

FairStock Score: 54/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham style investor, I start with business quality. UFP designs and makes medical disposables, sterile packaging, and engineered components. The filings show fiscal 2025 revenue of $602.8 million and net income of $68.3 million, or diluted EPS $8.75. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $174.0 million and net income $20.9 million, or $2.68 per diluted share, continuing sequential growth from fiscal Q1 2026, the quarter ended 2026-03-31, when revenue was $154.2 million and net income $17.5 million. That is a decent medtech niche, likely sticky once designed into procedures, but I do not see a wide moat from the figures alone. Financial health is solid: debt/equity 0.29, Piotroski 7/9, Altman Z 7.75, ROE 17.05%. However, ROCE 9.13% is modest, and FCF of $61.4 million gives only a 2.7% FCF yield. The market cap is $2.3B at the 2026-10-13 close of $294.29. FairStock's P/E is 31.82, P/B 4.93, EV/EBITDA 20.73, and PEG 17.58. The Graham Number is $111.47, implying a -164.01% margin of safety, so price is far above conservative value. The Lynch category is FAST GROWER based on five-year profit growth of 38.6% and revenue growth of 27.4%, but FairStock's recent revenue growth of 4.09% and profit growth of 1.81% show a sharp slowdown. I admire the balance sheet and profitability, but at this price the stock already discounts a lot. I would want either faster cash generation or a lower price before calling it a bargain.

In plain English: UFP Technologies makes custom medical products, sterile packaging, and engineered parts for healthcare companies. The business is profitable and has grown over the past few years, with little debt, but recent growth has cooled. At the current price, the stock looks expensive compared with its profits and cash flow.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q4 2025 10-K (period ended 2025-12-31) · fiscal Q3 2025 10-K (period ended 2025-09-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer